Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Any acute myeloid leukemia that has the chromosomal anomaly CEBPA gene mutation. (Mutation of the CEBPA gene encoding CCAAT/enhancer binding protein alpha. It is seen in acute myeloid leukemias usually associated with a normal karyotype.)
Biomarker and diagnostic research for acute myeloid leukemia, CEBPA gene mutation has been reported in the published literature.
No clinical trials have been registered for acute myeloid leukemia, CEBPA gene mutation.
17 publications have been identified in PubMed for acute myeloid leukemia, CEBPA gene mutation. Research spans Basic Science / Preclinical (29%), Diagnostic / Biomarker (18%), and Epidemiology / Natural History (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 5 | 29% |
Data assembled from 2 of 12 sources · Last updated Sep 19, 2026, 2:55 PM UTC
Common questions about acute myeloid leukemia, CEBPA gene mutation
Testing and diagnosis research
3 |
18% |
Disease patterns and progression | 3 | 18% |
Research summaries | 2 | 12% |
Patient case studies | 2 | 12% |
New treatment approaches | 2 | 12% |
Zhang K (2026). [PMID: 41595790](https://pubmed.ncbi.nlm.nih.gov/41595790/). *Biomedicines*. [Basic Science / Preclinical]
Rakiewicz T (2026). [PMID: 41769222](https://pubmed.ncbi.nlm.nih.gov/41769222/). *EJHaem*. [Review / Meta-Analysis]
Rigby E (2026). [PMID: 41823345](https://pubmed.ncbi.nlm.nih.gov/41823345/). *Biochem J*. [Gene Therapy / Novel Therapeutics]
Mousaei Ghasroldasht M (2025). [PMID: 39961276](https://pubmed.ncbi.nlm.nih.gov/39961276/). *Cancer Genet*. [Case Report / Case Series]
Shen Y (2025). [PMID: 40226311](https://pubmed.ncbi.nlm.nih.gov/40226311/). *Hum Mutat*. [Diagnostic / Biomarker]
Stelzner FMM (2025). [PMID: 41098861](https://pubmed.ncbi.nlm.nih.gov/41098861/). *Contemp Oncol (Pozn)*. [Basic Science / Preclinical]
Almaghrabi R (2025). [PMID: 40593493](https://pubmed.ncbi.nlm.nih.gov/40593493/). *Nat Commun*. [Gene Therapy / Novel Therapeutics]
Kovecses O (2025). [PMID: 40686853](https://pubmed.ncbi.nlm.nih.gov/40686853/). *Mol Ther Nucleic Acids*. [Diagnostic / Biomarker]
Song Y (2025). [PMID: 39927613](https://pubmed.ncbi.nlm.nih.gov/39927613/). *Mol Oncol*. [Basic Science / Preclinical]
Yu S (2025). [PMID: 40805192](https://pubmed.ncbi.nlm.nih.gov/40805192/). *Cancers (Basel)*. [Basic Science / Preclinical]